Chemistry:NLX-266

From HandWiki

NLX-266 is a biased agonist of the serotonin 5-HT1A receptor.[1][2] It acts specifically as a very-high-affinity and selective ERK1/2-biased serotonin 5-HT1A receptor agonist (Ki = 0.0447 nM; EC50 = 0.437 nM; Emax = 94%), with selectivity for ERK1/2 signaling over multiple other pathways.[2] The drug produces antidepressant- and antiparkinsonian-like effects in rodents, with much greater efficacy than certain other serotonin 5-HT1A receptor agonists like buspirone and gepirone.[2] It shows favorable pharmacokinetics in rodents.[2] The chemical synthesis of NLX-266 has been described.[2] NLX-266 was developed by Neurolixis.[1][2] It was first described in the scientific literature in 2025.[2]

See also

References

  1. ↑ 1.0 1.1 "Delving into the Latest Updates on NLX-266 with Synapse". 29 November 2025. https://synapse.patsnap.com/drug/8212e764b04e48c49af9850d6157477d. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Discovery of NLX-266, an Orally Available and Metabolically Stable ERK1/2-Biased 5-HT1AR Agonist with Superior Antidepressant and Antiparkinsonian Activity". Journal of Medicinal Chemistry 68 (9): 9706–9722. May 2025. doi:10.1021/acs.jmedchem.5c00484. PMID 40267318. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:NLX-266&oldid=4245982"